| Serial Number | 97003561 |
| Word Mark | EPAWAY |
| Filing Date | Tuesday, August 31, 2021 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, January 10, 2023 |
| Registration Number | 6946138 |
| Registration Date | Tuesday, January 10, 2023 |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, October 25, 2022 |
| Goods and Services | Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations for the treatment of respiratory conditions, namely, antibody for the treatment of Acute Respiratory Distress syndrome (ARDS), antibody for the treatment of Idiopathic Pulmonary Fibrosis (IPF), and Interstitial Lung Diseases (ILD); Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, (HAE) |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Saturday, September 10, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | CSL Behring GmbH |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Marburg D-35041 DE |
| Party Name | CSL Behring GmbH |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Marburg D-35041 DE |
| Party Name | CSL Behring GmbH |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Marburg D-35041 DE |
| Event Date | Event Description |
| Tuesday, January 10, 2023 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Tuesday, January 10, 2023 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, October 25, 2022 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, October 25, 2022 | PUBLISHED FOR OPPOSITION |
| Wednesday, October 5, 2022 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, September 20, 2022 | ELECTRONIC RECORD REVIEW COMPLETE |
| Friday, September 16, 2022 | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED |
| Thursday, September 15, 2022 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Saturday, September 10, 2022 | EXAMINER'S AMENDMENT ENTERED |
| Saturday, September 10, 2022 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Saturday, September 10, 2022 | EXAMINERS AMENDMENT E-MAILED |
| Saturday, September 10, 2022 | EXAMINERS AMENDMENT -WRITTEN |
| Tuesday, August 16, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, August 16, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, August 16, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, July 7, 2022 | ASSIGNED TO EXAMINER |
| Tuesday, March 8, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, March 8, 2022 | NON-FINAL ACTION E-MAILED |
| Tuesday, March 8, 2022 | NON-FINAL ACTION WRITTEN |
| Tuesday, March 1, 2022 | ASSIGNED TO EXAMINER |
| Monday, October 18, 2021 | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED |
| Monday, October 18, 2021 | ASSIGNED TO LIE |
| Friday, September 24, 2021 | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Thursday, October 14, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Friday, September 3, 2021 | NEW APPLICATION ENTERED IN TRAM |